Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity

• Main Authors: Evan Reed, Anna Karin Hedström, Monika Hansson, Linda Mathsson-Alm, Boel Brynedal, Saedis Saevarsdottir, Martin Cornillet, Per-Johan Jakobsson, Rikard Holmdahl, Karl Skriner, Guy Serre, Lars Alfredsson, Johan Rönnelid, Karin Lundberg
• Format: Article
• Language: English
• Published: BMC 2020-07-01
• Series: Arthritis Research & Therapy
• Subjects: Rheumatoid arthritis (RA); Autoantibodies; Anti-citrullinated protein antibodies (ACPA); Cyclic citrullinated peptide (CCP); Rheumatoid factor (RF); Anti-carbamylated protein antibodies (anti-CarP)
• Online Access: http://link.springer.com/article/10.1186/s13075-020-02191-2

Abstract Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative. Methods Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets. Results Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome. Conclusions “Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active treatment.